PA-BOOMI
8.5.2024 18:01:35 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end platform. Both these acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508324428/en/
Boomi Doubles Down on API Management with Key Acquisitions (Graphic: Business Wire)
“APIs are the backbone of modern software and application development, and have become a cornerstone of modern architectures that enable businesses to stay agile and compete effectively,” said Steve Lucas, CEO at Boomi. “However, cloud adoption and the explosive growth of APIs have disrupted traditional IT infrastructures. With these acquisitions, we’re putting an end to operational overhead and API sprawl by offering a robust, enterprise-grade and federated API management solution, giving customers the ability to quickly provision, discover, secure, and infinitely scale in one end-to-end enterprise platform.”
APIIDA Federated API Management
As the market-leading solution for federated API management, APIIDA’s API Control Plane expands Boomi’s portfolio by offering the ability for enterprises to discover, govern, and provision APIs from one central place, including APIs managed through gateways from various vendors. This allows a vendor-agnostic, federated administration of the entire API lifecycle, and can be adapted to the requirements of any organization, enabling a consistent consumer experience and governance across all APIs.
By offering federated API management, Boomi enables enterprises to:
- Reduce complexity and cost by unifying access to all their APIs across cloud-based and on-premises API gateways from multiple vendors
- Drive innovation with a single destination for application developers, simplifying API consumption and accelerating time-to-market by giving developers a dynamic catalog where APIs can be discovered and reused
- Enhance provider security and governance with total visibility and control over all their APIs
“Companies that rely on a manual, fragmented approach to registering, managing, and publishing APIs across distributed platforms risk having those APIs be undiscovered, overlooked, and hence unadopted by users and applications that could benefit from them,” said Jaime Ryan, Vice President of Product, API Management at Boomi. “To successfully enable digital transformation, businesses need a proven, reliable way to connect applications and other data sources. With federated API management, customers will be able to reduce time to value with a single control plane for wherever APIs are deployed, providing better discovery, governance, and collaboration while making existing APIs more visible, subscribable, and consumable.”
API Management Assets From Cloud Software Group
Further accelerating the company’s API management roadmap, Boomi has also acquired assets from Cloud Software Group, providing Boomi customers enterprise-grade scalability and security. These assets, developed by a team that helped invent the API economy and used by some of the world’s largest organizations, will enable the Boomi Enterprise Platform to support even the most demanding API management performance and security requirements in markets such as travel, retail, tech, finance, and healthcare.
Additional Resources
- Read more about Boomi’s latest acquisitions
- Follow Boomi on X, LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508324428/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom